Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $268.1MThe company’s own SEC segment disclosure.
- Nuplazid$166.9M62%
- Daybue$101.1M38%
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $268M in Q1 2026 (quarter ended March 31, 2026), up 9.7% from the same quarter a year earlier. That came with a gross margin of 91% and net income of $3.6M (1.4% of revenue). For the full year FY2025, revenue was $1.07B (+12% year on year) and net income $391M. Its largest product in 2026-Q1 was Nuplazid at $167M, 62% of the disclosed total, just ahead of Daybue at 38%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.